<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000046190"><TermName>hu14.18-interleukin-2 fusion protein</TermName><TermPronunciation>(… in-ter-LOO-kin-2 FYOO-zhun PROH-teen)</TermPronunciation><TermDefinition><DefinitionText>An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000731427" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;hu14.18-interleukin-2 fusion protein&quot;" language="en" id="_3"/><MediaLink ref="CDR0000731426" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;proteína de fusión de la interleucina 2 con hu14.18&quot;" language="es" id="_4"/><SpanishTermName>proteína de fusión de la interleucina 2 con hu14.18</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento contra el cáncer en el cual se combina hu14.18 (un anticuerpo monoclonal) con la interleucina-2. El anticuerpo monoclonal se une a las células cancerosas y produce la IL-2, que estimula el sistema inmunitario para que destruya las células cancerosas.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition></GlossaryTerm>
